Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On June 23, 2025, Dr. Reddy’s Laboratories announced the allotment of 10,685 equity shares to eligible employees as part of their Employee Stock Options Schemes. This move reflects the company’s commitment to employee incentives and aligns with regulatory compliance, potentially enhancing employee engagement and retention.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients, and biosimilars, catering to a global market.
Average Trading Volume: 2,113,488
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.73B
Learn more about RDY stock on TipRanks’ Stock Analysis page.